135 related articles for article (PubMed ID: 38870939)
1. Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design.
Mukherjee M; Day PJ; Laverty D; Bueren-Calabuig JA; Woodhead AJ; Griffiths-Jones C; Hiscock S; East C; Boyd S; O'Reilly M
Structure; 2024 Jun; ():. PubMed ID: 38870939
[TBL] [Abstract][Full Text] [Related]
2. The crystal structure of human CDK7 and its protein recognition properties.
Lolli G; Lowe ED; Brown NR; Johnson LN
Structure; 2004 Nov; 12(11):2067-79. PubMed ID: 15530371
[TBL] [Abstract][Full Text] [Related]
3. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
Song X; Fang C; Dai Y; Sun Y; Qiu C; Lin X; Xu R
Br J Cancer; 2024 May; 130(8):1239-1248. PubMed ID: 38355840
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H.
Higashi H; Suzuki-Takahashi I; Saitoh S; Segawa K; Taya Y; Okuyama A; Nishimura S; Kitagawa M
Eur J Biochem; 1996 Apr; 237(2):460-7. PubMed ID: 8647086
[TBL] [Abstract][Full Text] [Related]
8. 2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942.
Greber BJ; Remis J; Ali S; Nogales E
Biophys J; 2021 Feb; 120(4):677-686. PubMed ID: 33476598
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
Liu S; Bolger JK; Kirkland LO; Premnath PN; McInnes C
ACS Chem Biol; 2010 Dec; 5(12):1169-82. PubMed ID: 20843055
[TBL] [Abstract][Full Text] [Related]
10. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022).
Kovalová M; Baraka JP; Mik V; Jorda R; Luo L; Shao H; Kryštof V
Expert Opin Ther Pat; 2023 Feb; 33(2):67-87. PubMed ID: 36975020
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop.
Garrett S; Barton WA; Knights R; Jin P; Morgan DO; Fisher RP
Mol Cell Biol; 2001 Jan; 21(1):88-99. PubMed ID: 11113184
[TBL] [Abstract][Full Text] [Related]
12. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.
Argiriadi MA; Goedken ER; Banach D; Borhani DW; Burchat A; Dixon RW; Marcotte D; Overmeyer G; Pivorunas V; Sadhukhan R; Sousa S; Moore NS; Tomlinson M; Voss J; Wang L; Wishart N; Woller K; Talanian RV
BMC Struct Biol; 2012 Sep; 12():22. PubMed ID: 22995073
[TBL] [Abstract][Full Text] [Related]
13. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
14. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy.
Liang H; Du J; Elhassan RM; Hou X; Fang H
Expert Opin Investig Drugs; 2021 Jan; 30(1):61-76. PubMed ID: 33183110
[No Abstract] [Full Text] [Related]
15. Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach.
George Priya Doss C; Nagasundaram N; Chakraborty C; Chen L; Zhu H
Hum Genomics; 2013 Apr; 7(1):10. PubMed ID: 23561625
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for CDK7 activation by MAT1 and Cyclin H.
Peissert S; Schlosser A; Kendel R; Kuper J; Kisker C
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26739-26748. PubMed ID: 33055219
[TBL] [Abstract][Full Text] [Related]
17. Meiotic expression of the cyclin H/Cdk7 complex in male germ cells of the mouse.
Kim JM; McGaughy JT; Bogle RK; Ravnik SE
Biol Reprod; 2001 May; 64(5):1400-8. PubMed ID: 11319144
[TBL] [Abstract][Full Text] [Related]
18. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
19. In vivo potentiation of human oestrogen receptor alpha by Cdk7-mediated phosphorylation.
Ito S; Takeyama K; Yamamoto A; Sawatsubashi S; Shirode Y; Kouzmenko A; Tabata T; Kato S
Genes Cells; 2004 Oct; 9(10):983-92. PubMed ID: 15461668
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
Wang M; Wang T; Zhang X; Wu X; Jiang S
Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
